CoChat

MRK-409 (MK-0343), a GABAAreceptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans

Open access
Atack, JR, Wafford, KA, Street, LJ, Dawson, GR, Tye, S, Van Laere, K, Bormans, G, Sanabria-Bohórquez, SM, De Lepeleire, I, de Hoon, JN, Van Hecken, A, Burns, HD, McKernan, RM, Murphy, MG, Hargreaves, RJ · 2011 · Journal of Psychopharmacology
Cited by 60

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

MRK-409 binds to α1-, α2-, α3- and α5-containing human recombinant GABA A receptors with comparable high affinity (0.21–0.40 nM). However, MRK-409 has greater agonist efficacy at the α3 compared with α1 subtypes (respective efficacies relative to the full agonist chlordiazepoxide of 0.45 and 0.18). This compound readily penetrates the brain in rats and occupies the benzodiazepine site of GABA A receptors, measured using an in vivo [3 H]flumazenil binding assay, with an Occ 50 of 2.2 mg/kg p.o. and a corresponding plasma EC 50 of 115 ng/mL. Behaviourally, the α3-preferring agonist efficacy profile of MRK-409 produced anxiolytic-like activity in rodent and primate unconditioned and conditioned models of anxiety with minimum effective doses corresponding to occupancies, depending on the particular model, ranging from ∼35% to 65% yet there were minimal overt signs of sedation at occupancies greater than 90%. In humans, however, safety and tolerability studies showed that there was pronounced sedation at a dose of 2 mg, resulting in a maximal tolerated dose of 1 mg. This 2 mg dose corresponded to a C max plasma concentration of 28 ng/mL, which, based on the rodent plasma EC 50 for occupancy of 115 ng/mL, suggested that sedation in humans occurs at low levels of occupancy. This was confirmed in human positron emission tomography studies, in which [11 C]flumazenil uptake following a single dose of 1 mg MRK-409 was comparable to that of placebo, indicating that occupancy of GABA A receptor benzodiazepine binding sites by MRK-409 was below the limits of detection (i.e. <10%). Taken together, these data show that MRK-409 causes sedation in humans at a dose (2 mg) corresponding to levels of occupancy considerably less than those predicted from rodent models to be required for anxiolytic efficacy (∼35–65%). Thus, the preclinical non-sedating anxiolytic profile of MRK-409 did not translate into humans and further development of this compound was halted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0269881109354927

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 60

Metadata

Authors
Atack, Jr., Wafford, K., Street, L., Dawson, G., Tye, S., Van Laere, K., Bormans, G., Sanabria-Bohórquez, S., De Lepeleire, I., de Hoon, J., Van Hecken, A., Burns, H., McKernan, R., Murphy, M., & Hargreaves, R.
Venue
Journal of Psychopharmacology
Published
2010-02-10
Volume
25
Issue
3
Pages
314-328
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2008215214
Cited by
60
References
9
FWCI
2.34
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MRK-409 (MK-0343), a GABAAreceptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans. https://app.cochat.ai/papers/10.1177/0269881109354927
The paper
Atack, Jr., Wafford, K., Street, L., Dawson, G., Tye, S., Van Laere, K., Bormans, G., Sanabria-Bohórquez, S., De Lepeleire, I., de Hoon, J., Van Hecken, A., Burns, H., McKernan, R., Murphy, M., & Hargreaves, R. (2011). MRK-409 (MK-0343), a GABAAreceptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans. Journal of Psychopharmacology. https://doi.org/10.1177/0269881109354927

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.